Lenvatinib

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

[1]Kudo M, et al. Lenvatinib versus Bay 43-9006 in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.|[2]Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.|[3]Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671.|[4]Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.Acta Pharm. 2024 Sep 14;74(3):441-459.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Healthc Mater. 2024 Oct 2:e2401398.|Adv Sci (Weinh). 2024 Jul 9:e2402327.|Am J Cancer Res. 2023 Nov 15;13(11):5368-5381.|Apoptosis. 2024 May 14.|Biodes Manuf. 17 July 2021.|Bioengineered. 2024 Dec;15(1):2296775.|Biomed Pharmacother. 2022 Jan;145:112391.|bioRxiv. 2023 Nov 17.|Cancers (Basel). 2023 Oct 22, 15(20), 5097.|Cell Death Dis. 2024 Jul 5;15(7):484.|Cell Death Discov. 2021 Nov 18;7(1):359.|Cell Signal. 2023 Jul 28;110828.|Drug Resist Updat. 2023 Jul;69:100976.|Ecotoxicol Environ Saf. 2024 Sep 27:285:117031.|EMBO J. 2021 Apr 28;e106771.|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Front Biosci (Landmark Ed). 2024 Jan 19, 29(1), 3.|Front Oncol. 2021 Jul 13;11:704042.|Front Oncol. 2022 Sep 8:12:944537.|Front Pharmacol. 2024 Apr 5.|Fundam Clin Pharmacol. 2021 Feb 1.|Int J Biol Sci. 2023 Apr 23; 19(7): 2270-2288.|Int J Mol Sci. 2022 Sep 14;23(18):10677.|J Cell Mol Med. 2021 Jan;25(1):549-560.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.|J Extracell Vesicles. 2024 Jul;13(7):e12468.|J Mol Neurosci. 2020 Sep;70(9):1437-1444.|J Oncol. 2022 Oct 18;2022:4537343.|J Transl Med. 2022 Mar 7;20(1):116.|J Transl Med. 2023 Jan 9;21(1):9.|Liver Int. 2023 May 19.|Mar Drugs. 2024 Sep 28;22(10):444.|Med Oncol. 2021 Mar 17;38(4):41.|Med Oncol. 2020 Mar 12;37(4):24.|MedComm. 26 August 2022.|Mol Ther. 2023 May 4;S1525-0016(23)00253-8.|Oncogene. 2024 Sep 9.|PeerJ. 2023 Jan 25;11:e14610.|Phytomedicine. 2024 Jul 25:130:155767.|Res Sq. 2024 Nov 18.|Research Square Preprint. 2021 May.|Research Square Preprint. 2023 Aug 5.|Research Square Print. 2022 Aug.|Research Square Print. 2022 May.|Research Square Print. 2023 Jan 9th,|Sci Rep. 2022 Jun 15;12(1):9951.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|SSRN. 2023 Apr 24.|Transl Res. 2024 May 24:S1931-5244(24)00107-5.|J Med Chem. 2024 Jun 25.